{"id":933536,"date":"2026-02-03T07:08:34","date_gmt":"2026-02-03T12:08:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\/"},"modified":"2026-02-03T07:08:34","modified_gmt":"2026-02-03T12:08:34","slug":"caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\/","title":{"rendered":"CareDx to Present AlloHeme\u2122 Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>CareDx to Present AlloHeme\u2122 Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings<\/b><\/p>\n<p><i>Company to host investor webcast and conference call on<b \/>February 12 at 7 a.m. PT \/ 10 a.m. ET<\/i><\/p>\n<p><i>Investor webcast will feature the clinical validation data and review commercial launch timeline<\/i><\/p>\n<p>BRISBANE, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nCareDx, Inc. (Nasdaq: CDNA) \u2014 The Transplant Company\u2122, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high\u2011value healthcare solutions for transplant patients and caregivers, today announced that pivotal clinical validation data from the ACROBAT study (NCT04635384) will be presented at the 2026 Tandem Meetings, Transplantation &amp; Cellular Therapy Meetings of ASTCT\u2122 and CIBMTR\u00ae, held February 4-7, 2026, in Salt Lake City, Utah.<\/p>\n<p>\nThe ACROBAT study is a prospective, multi-center, blinded clinical trial evaluating AlloHeme, CareDx\u2019s AI-powered next-generation sequencing (NGS)-based peripheral blood test for monitoring relapse after allogeneic hematopoietic cell transplantation (HCT) in patients with hematologic malignancies. AlloHeme identifies cancer relapse ahead of traditional detection methods, potentially enabling timely clinical interventions. The ACROBAT study includes patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) monitored with AlloHeme for cancer relapse at 11 hematopoietic stem cell transplant centers across the U.S.<\/p>\n<p>\nThe oral presentation will feature the complete 24-month follow-up results, building upon 18-month interim results published in the conference abstract, available online <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdistribution.us.m-anage.com%2Ffrom.storage%3Fimage%3DiI8mZKVyQCOb0f6sZEQvovGqcJhffx0cW1R-ZLv1tpRJq1HROdzhWdqubav3sN8t0&amp;esheet=54412621&amp;newsitemid=20260203634748&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=1a44df5139f003c461b020946f90ddc0\">here<\/a>.<\/p>\n<p>\nIn addition, on February 12, 2025, CareDx will host an investor webcast and conference call to discuss the study findings and commercial launch timeline.<\/p>\n<p>\nTandem Presentation Details:<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Presentation ID <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftandem.virtual-meeting.org%2Fprogramme%2Fpresentation%2F677640&amp;esheet=54412621&amp;newsitemid=20260203634748&amp;lan=en-US&amp;anchor=61&amp;index=2&amp;md5=5c7d7afcab26b8a8a64f4206c5a79899\">61<\/a>:<\/b> Acrobat Interim Results: Peripheral Blood-Based AlloHeme Test Enables Robust Relapse Surveillance in Post-HCT AML and MDS Patients\n<\/li>\n<li><b>Presenter: <\/b>Dr. Ran Reshef, Professor of Medicine at Columbia University and Director of Translational Research, Blood and Marrow Transplantation Program at Herbert Irving Comprehensive Cancer Center\n<\/li>\n<li><b>Date &amp; Time:<\/b> Friday, February 6, 3:15 p.m. MT\n<\/li>\n<li><b>Location:<\/b> Ballroom I, Salt Palace Convention Center\n<\/li>\n<\/ul>\n<p><b>Investor Webcast Details:<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Presentation: <\/b>AlloHeme Clinical Validation Data Review and Launch Timeline\n<\/li>\n<li><b>Date &amp; Time: <\/b>Wednesday, February 12, 7 a.m. PT \/ 10 a.m. ET\n<\/li>\n<li>\nThe one-hour event will feature presentations by members of the CareDx\u2019s leadership team and ACROBAT study site Principal Investigator, Dr. Ran Reshef.<\/p>\n<\/li>\n<li>\nA live and archived webcast can be accessed on the Events &amp; Presentations section of CareDx\u2019s Investor Relations website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.caredx.com%2Fevents-and-presentations%2Fdefault.aspx&amp;esheet=54412621&amp;newsitemid=20260203634748&amp;lan=en-US&amp;anchor=investors.caredx.com&amp;index=3&amp;md5=7f12c9ff2aa758979e325596df437898\">investors.caredx.com<\/a>. To participate in the live conference call via telephone, register <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fregistrations.events%2Fdirect%2FQ4I888846505&amp;esheet=54412621&amp;newsitemid=20260203634748&amp;lan=en-US&amp;anchor=here&amp;index=4&amp;md5=3dd915c4dae03237a879bb034c3d0b92\">here<\/a>. Upon registering, a dial-in number and unique PIN will be provided.<\/p>\n<\/li>\n<\/ul>\n<p><b>About CareDx<\/b><\/p>\n<p>\nCareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company\u2019s integrated solutions include non\u2011invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics\u2011based information for transplant patients. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.caredx.com%2F&amp;esheet=54412621&amp;newsitemid=20260203634748&amp;lan=en-US&amp;anchor=www.caredx.com&amp;index=5&amp;md5=3e1eb5a62e1c3316acd2588555d85ad2\">www.caredx.com<\/a>.<\/p>\n<p><b>Forward Looking Statements<\/b><\/p>\n<p>\nThis press release includes forward-looking statements related to CareDx including statements regarding the potential benefits and results that may be achieved with AlloHeme. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of AlloHeme are, risks that the findings in the ACROBAT study supporting the data may be inaccurate, general economic and market factors, and other risks discussed in CareDx\u2019s filings with the Securities and Exchange Commission (the \u201cSEC\u201d), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by CareDx with the SEC on February 28, 2025, the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 filed by CareDx with the SEC on November 4, 2025, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx\u2019s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx\u2019s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260203634748r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260203634748\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260203634748\/en\/<\/a><\/span><\/p>\n<p><b>CareDx, Inc.<br \/>\n<\/b><br \/>Media<br \/>\n<br \/>Natasha Moshirian Wagner<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:nwagner@CareDx.com\"><b>nwagner@CareDx.com<br \/>\n<\/b><\/a><b><br \/><\/b><br \/>Investor Relations<br \/>\n<br \/>Caroline Corner<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investor@CareDx.com\"><b>investor@CareDx.com<\/b><\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California Utah<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Pharmaceutical Clinical Trials Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260203634748\/en\/2559419\/3\/CareDx_updated_logo_2025.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>CareDx to Present AlloHeme\u2122 Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings Company to host investor webcast and conference call onFebruary 12 at 7 a.m. PT \/ 10 a.m. ET Investor webcast will feature the clinical validation data and review commercial launch timeline BRISBANE, Calif.&#8211;(BUSINESS WIRE)&#8211; CareDx, Inc. (Nasdaq: CDNA) \u2014 The Transplant Company\u2122, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high\u2011value healthcare solutions for transplant patients and caregivers, today announced that pivotal clinical validation data from the ACROBAT study (NCT04635384) will be presented at the 2026 Tandem Meetings, Transplantation &amp; Cellular Therapy Meetings of ASTCT\u2122 and CIBMTR\u00ae, held February 4-7, 2026, in Salt Lake City, Utah. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CareDx to Present AlloHeme\u2122 Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-933536","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CareDx to Present AlloHeme\u2122 Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CareDx to Present AlloHeme\u2122 Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CareDx to Present AlloHeme\u2122 Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings Company to host investor webcast and conference call onFebruary 12 at 7 a.m. PT \/ 10 a.m. ET Investor webcast will feature the clinical validation data and review commercial launch timeline BRISBANE, Calif.&#8211;(BUSINESS WIRE)&#8211; CareDx, Inc. (Nasdaq: CDNA) \u2014 The Transplant Company\u2122, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high\u2011value healthcare solutions for transplant patients and caregivers, today announced that pivotal clinical validation data from the ACROBAT study (NCT04635384) will be presented at the 2026 Tandem Meetings, Transplantation &amp; Cellular Therapy Meetings of ASTCT\u2122 and CIBMTR\u00ae, held February 4-7, 2026, in Salt Lake City, Utah. &hellip; Continue reading &quot;CareDx to Present AlloHeme\u2122 Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-03T12:08:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260203634748r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CareDx to Present AlloHeme\u2122 Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings\",\"datePublished\":\"2026-02-03T12:08:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\\\/\"},\"wordCount\":770,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260203634748r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\\\/\",\"name\":\"CareDx to Present AlloHeme\u2122 Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260203634748r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-02-03T12:08:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260203634748r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260203634748r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CareDx to Present AlloHeme\u2122 Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CareDx to Present AlloHeme\u2122 Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\/","og_locale":"en_US","og_type":"article","og_title":"CareDx to Present AlloHeme\u2122 Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings - Market Newsdesk","og_description":"CareDx to Present AlloHeme\u2122 Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings Company to host investor webcast and conference call onFebruary 12 at 7 a.m. PT \/ 10 a.m. ET Investor webcast will feature the clinical validation data and review commercial launch timeline BRISBANE, Calif.&#8211;(BUSINESS WIRE)&#8211; CareDx, Inc. (Nasdaq: CDNA) \u2014 The Transplant Company\u2122, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high\u2011value healthcare solutions for transplant patients and caregivers, today announced that pivotal clinical validation data from the ACROBAT study (NCT04635384) will be presented at the 2026 Tandem Meetings, Transplantation &amp; Cellular Therapy Meetings of ASTCT\u2122 and CIBMTR\u00ae, held February 4-7, 2026, in Salt Lake City, Utah. &hellip; Continue reading \"CareDx to Present AlloHeme\u2122 Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-03T12:08:34+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260203634748r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CareDx to Present AlloHeme\u2122 Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings","datePublished":"2026-02-03T12:08:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\/"},"wordCount":770,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260203634748r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\/","name":"CareDx to Present AlloHeme\u2122 Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260203634748r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-02-03T12:08:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260203634748r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260203634748r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-alloheme-pivotal-clinical-validation-data-in-hematologic-cancer-relapse-detection-at-2026-tandem-meetings\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CareDx to Present AlloHeme\u2122 Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933536","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=933536"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933536\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=933536"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=933536"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=933536"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}